Procardia

Anal sphincter hypertonia, Proctalgia, Altitude Sickness + 12 more

Treatment

3 FDA approvals

20 Active Studies for Procardia

What is Procardia

Nifedipine

The Generic name of this drug

Treatment Summary

Nifedipine (also known as BAY a 1040) is a type of medication that blocks the flow of calcium into certain cells in the body. It is used to treat high blood pressure and chest pain. Nifedipine was developed by Bayer in 1972, and is one of the earliest types of calcium channel blockers. Since then, newer versions have been developed with slower onset and longer duration of action. Nifedipine was approved by the FDA in 1981.

Procardia

is the brand name

image of different drug pills on a surface

Procardia Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Procardia

Nifedipine

1981

355

Approved as Treatment by the FDA

Nifedipine, otherwise called Procardia, is approved by the FDA for 3 uses like Angina, Stable and Failed conventional therapy .

Angina, Stable

Helps manage Chronic Stable Angina Pectoris

Failed conventional therapy

Helps manage Failed conventional therapy

Vasospastic Angina

Helps manage Vasospastic Angina

Effectiveness

How Procardia Affects Patients

Nifedipine is a medicine that helps lower blood pressure and increases oxygen supply to the heart. It should be taken three times a day, usually in doses of 10-120mg. Patients should be aware that taking nifedipine can cause low blood pressure, chest pain, and a heart attack.

How Procardia works in the body

Nifedipine works by blocking calcium ions from entering cells in blood vessels. This reduces the resistance in blood vessels, lowers blood pressure, and increases the oxygen supply to the heart, helping to relieve angina.

When to interrupt dosage

The advisable dosage of Procardia is contingent upon the identified affliction, including Achalasia, Ureteral Calculus and Hypertensive diseases. The measure of dosage fluctuates as indicated by the administration means (e.g. Tablet, film coated, extended release or Capsule) laid out in the table beneath.

Condition

Dosage

Administration

Ureteral Calculi

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Angina, Stable

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Fissure in Ano

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Vasospastic Angina

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Failed conventional therapy

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Proctalgia

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Pulmonary Edema

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Altitude Sickness

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Raynaud Disease

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Hypertensive disease

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Hypertensive Emergency

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Anal sphincter hypertonia

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Obstetric Labor, Premature

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Esophageal Achalasia

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Pulmonary Hypertension

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Warnings

Procardia has one contraindication. It must not be employed with the conditions listed in the following table.

Procardia Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Nifedipine may interact with Pulse Frequency

There are 20 known major drug interactions with Procardia.

Common Procardia Drug Interactions

Drug Name

Risk Level

Description

Amitriptyline

Major

The metabolism of Amitriptyline can be decreased when combined with Nifedipine.

Amoxapine

Major

The metabolism of Amoxapine can be decreased when combined with Nifedipine.

Anagrelide

Major

The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Anagrelide.

Arsenic trioxide

Major

The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Arsenic trioxide.

Artemether

Major

The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Artemether.

Procardia Toxicity & Overdose Risk

The toxic dose of the drug in rats has been found to be 1022mg/kg and in mice is 202mg/kg. Symptoms of an overdose include low blood pressure, abnormal heartbeat rhythms, and rapid heartbeat. Treatment for overdose includes monitoring breathing and heart rate, raising the patient’s limbs, and providing medications to increase blood pressure, fluids, and calcium.

image of a doctor in a lab doing drug, clinical research

Procardia Novel Uses: Which Conditions Have a Clinical Trial Featuring Procardia?

101 active clinical trials are currently underway to assess the potential of Procardia in alleviating Achalasia, Hypertensive Emergencies and Anal Fissures.

Condition

Clinical Trials

Trial Phases

Obstetric Labor, Premature

2 Actively Recruiting

Not Applicable

Pulmonary Edema

0 Actively Recruiting

Hypertensive disease

27 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3

Angina, Stable

0 Actively Recruiting

Esophageal Achalasia

0 Actively Recruiting

Altitude Sickness

0 Actively Recruiting

Raynaud Disease

1 Actively Recruiting

Phase 4

Pulmonary Hypertension

31 Actively Recruiting

Phase 2, Phase 3, Not Applicable, Phase 1

Proctalgia

0 Actively Recruiting

Hypertensive Emergency

1 Actively Recruiting

Phase 4

Fissure in Ano

0 Actively Recruiting

Vasospastic Angina

1 Actively Recruiting

Phase 2, Phase 3

Anal sphincter hypertonia

0 Actively Recruiting

Ureteral Calculi

0 Actively Recruiting

Failed conventional therapy

0 Actively Recruiting

Procardia Reviews: What are patients saying about Procardia?

4

Patient Review

10/11/2010

Procardia for Early Labor

I had a stillborn baby as a result of this drug. I was full term and my baby died on Feb 22, 2010. Her name was Katlyn Kiser.

3.7

Patient Review

9/16/2013

Procardia for Occasional Numbness, Prickling, or Tingling of Fingers and Toes

I have tachycardia

3.3

Patient Review

1/23/2011

Procardia for Occasional Numbness, Prickling, or Tingling of Fingers and Toes

I developed allergic lumps

2.3

Patient Review

3/22/2010

Procardia for Early Labor

My doctor put me on this when they found out I was pregnant. It helped keep my blood pressure down and I had no adverse effects while taking it.

2

Patient Review

4/20/2011

Procardia for Early Labor

I went into premature labor after a car accident when I was only seven months pregnant. Thankfully, this medication helped me carry my baby to full-term.

2

Patient Review

8/22/2013

Procardia for Angina

I've found that Procardia has given me upset stomach more often than not, including gas and bloating. Sometimes it even affects my bowel movements painfully.

1.7

Patient Review

6/2/2011

Procardia for Early Labor

I started getting headaches (which I never get), feeling depressed and anxious (also not usual for me), and hives (I do sometimes get hives) within a month of starting this medication.

1.7

Patient Review

2/9/2020

Procardia for Occasional Numbness, Prickling, or Tingling of Fingers and Toes

This didn't help my Raynaud's at all.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about procardia

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the side effects of taking nifedipine?

"The following are symptoms of an overdose: bloating or swelling of the face, arms, hands, lower legs, or feet, difficult or labored breathing, dizziness or lightheadedness, fast, irregular, pounding, or racing heartbeat or pulse, feeling of warmth, headache, muscle cramps, and shakiness in the legs, arms, hands, or feet."

Answered by AI

What is Procardia used for?

"This medication is for preventing chest pain (angina). It may help you to exercise more and decrease how often you have angina attacks. Nifedipine belongs to a class of medications called calcium channel blockers. It works by relaxing blood vessels so blood can flow more easily."

Answered by AI

Does Procardia lower blood pressure?

"Nifedipine (Procardia XL) is a medication that works by relaxing blood vessels, which lowers blood pressure and increases oxygen to the heart. Nifedipine (Procardia XL) is classified as a calcium channel blocker (CCB)."

Answered by AI

Is Procardia a blood pressure pill?

"Procardia is a medication used to lower blood pressure and treat chest pain. It is in a class of drugs known as calcium channel blockers. Procardia is available in generic form."

Answered by AI

Clinical Trials for Procardia

Image of Miles Square Health Center Chicago in Chicago, United States.

Food is Medicine for High Blood Pressure and Obesity

Any Age
All Sexes
Chicago, IL

The goal of this clinical trial is to treat both hypertension and obesity in adults using a food is medicine framework. Participants will be randomized 1:1 to FIM+DASH or usual-care control. The 24-week trial includes a 12-week FIM+DASH intervention followed by a 12-week maintenance period and leverages existing partnerships with community-based organizations for home food delivery and culinary skill-skill building. The main questions it aims to answer are: (1) What is the effect of FIM+DASH vs. usual care control on blood pressure? (2) What is the effect of FIM+DASH vs. usual care control on DASH diet adherence (diet quality), body weight, and waist circumference? (3) How to identify factors associated with the sustainability and scalability of FIM+DASH in real-world settings?

Phase 2
Waitlist Available

Miles Square Health Center Chicago (+3 Sites)

Image of U Health in Miami, United States.

Cuffless PPG Monitor for High Blood Pressure

18+
All Sexes
Miami, FL

This study aims to validate the accuracy and reliability of blood pressure (BP) estimates obtained over 24 hours using a PPG-based chest-patch device compared to the gold standard ambulatory blood pressure monitoring (ABPM) method using an upper arm cuff-based oscillometric BP device, in both hypertensive and normotensive individuals referred by their provider to undergo a 24-hours ABPM for clinical indication. The Awake/Asleep test, which is the primary test recommended for automated wearable cuffless BP devices that are cuff-calibrated (based on the 2023 European Society of Hypertension (ESH) recommendations for the validation of cuffless blood pressure measuring devices), will be conducted in this study. The secondary aim of the study is to assess the feasibility and convenience of the PPG-based device.

Waitlist Available
Has No Placebo

U Health (+1 Sites)

Ziad Zoghby, M.D., M.B.A.

Biobeat Technologies Ltd.

Image of UPMC Presybeterian in Pittsburgh, United States.

Telaglenastat for Pulmonary Hypertension

18 - 75
All Sexes
Pittsburgh, PA

The research study is being conducted to evaluate the effectiveness of a drug called Telaglenastat in adults diagnosed with Pulmonary Hypertension (PH). PH is a progressive condition that affects the arteries in the lungs, specifically the pulmonary arteries, which carry blood from the right side of the heart to the lungs. Telaglenastat is not currently approved by the Food and Drug Administration for the treatment of PH. However, the study investigators believe that Telaglenastat may help lower blood pressure in the lungs and improve both heart and lung function. It is important to note that the drug will not be available to participants once the study concludes.

Phase 1 & 2
Waitlist Available

UPMC Presybeterian

Michael Risbano, MD

Have you considered Procardia clinical trials?

We made a collection of clinical trials featuring Procardia, we think they might fit your search criteria.
Go to Trials
Image of University of Alabama at Birmingham in Birmingham, United States.

Dietary Interventions for Hypertension

18+
All Sexes
Birmingham, AL

Natriuretic peptides (NPs) are hormones produced by the heart and play an important role in maintaining cardiovascular health and have favorable metabolic benefits. Low NP levels are associated with an increased likelihood of the development of cardiometabolic diseases like diabetes and hypertension. NP levels are known to be highly heritable, with up to half of the differences in NP levels being explained by genetics. The investigators aim to describe the genetic architecture of NPs by examining the genetic variants associated with NPs, and generate and validate a polygenic score (PGS) for NPs. The investigators will use this NP PGS to examine the association of genetically determined NP levels with cardiometabolic and cardiovascular outcomes. The investigators will conduct a genotype-guided physiological clinical trial that aims to assess the genetic factors affecting NP levels and their impact on blood pressure and NP response to saline infusion, high-salt diet, and low-salt diet. These findings will help support personal medicine approaches to lower the increasing burden of hypertension in the United States.

Waitlist Available
Has No Placebo

University of Alabama at Birmingham

Pankaj Arora, MD, FAHA

Have you considered Procardia clinical trials?

We made a collection of clinical trials featuring Procardia, we think they might fit your search criteria.
Go to Trials
Image of UCSF Health St. Mary's Hospital in San Francisco, United States.

PF-07868489 for Pulmonary Hypertension

18+
All Sexes
San Francisco, CA

The purpose of this study is to learn about the long-term safety, tolerability and effects of the study medicine (PF-07868489) for the possible treatment of PAH. PAH is a condition in which there is high blood pressure in the arteries that carry blood from the heart to the lungs. This high pressure makes it harder for the heart to pump blood through those lungs, potentially damaging the right side of the heart. This is an open-label study. Which means that both the healthcare providers and the study participants are aware of the medicine being given. This study is also an extension study with study medicine (PF-07868489). An extension study allows patients from an earlier clinical study (also called as qualifying study) to continue participating to assess long-term benefits and safety of the medicine.

Phase 2
Recruiting

UCSF Health St. Mary's Hospital (+6 Sites)

Pfizer CT.gov Call Center

Pfizer

Have you considered Procardia clinical trials?

We made a collection of clinical trials featuring Procardia, we think they might fit your search criteria.
Go to Trials